Conférence

CRCHUM

Université de Montréal

AXE NEUROSCIENCES

CONFÉRENCIER

Jean-Pierre Julien, Ph. D.

Fellow of the Royal Society of Canada
Fellow of the Canadian Academy of Health Sciences
Canada Research Chair in Neurodegeneration
CERVO Brain Research Centre
Department of Psychiatry and Neuroscience
Laval University



Development of antibody approaches to target TDP-43 pathology in ALS and dementia

Amyotrophic lateral sclerosis (ALS) is a fatal neurologic disease characterized by progressive degeneration of motor neurons that leads to paralysis and death within 3-5 years following onset. Only few drugs are available for ALS and they confer only modest slowing of disease. In both familial and sporadic ALS cases, affected neurons exhibit cytoplasmic accumulations of a protein called TDP-43. Few years ago, we generated a mouse monoclonal antibody against TDP-43 which is unique in that it recognizes cytoplasmic TDP-43 but not nuclear TDP-43. From this monoclonal antibody, we have also derived a single chain antibody (scFv) which can be delivered to neurons via AAV-mediated transduction. Our results suggest that treatments based on scFv antibody or full length antibody targeting TDP-43 can confer therapeutic effects in various mouse models of ALS and dementia.

Le mardi 14 mars à 9 h
Heure normale de l'Est (États-Unis et Canada)

Amphithéâtre du CRCHUM, R.05.212A
900 rue Saint-Denis
Montréal (QC)

L'AUDACE DE CHERCHER PLUS LOIN

Séminaire organisé par Christine Vande Velde
Information : c.vande.velde@umontreal.ca